***Background.*** Urinary tract infections (UTIs) are frequently encountered in clinical practice and most commonly caused by *E*. *coli* and other Gram negative uropathogens. Given current concerns about cost of treatment and antimicrobial resistance, rapid confirmation of bacteriuria in patients under consideration for empiric treatment of UTI would potentially reduce expenditures and unnecessary antimicrobial treatment. Current diagnostic methods are suboptimal: nitrite dipsticks have low sensitivity and specificity and cultures take days. We tested a rapid immunoassay for bacteriuria developed by Silver Lake Research Corporation (SLRC) in comparison with standard bacterial culture using urine specimens submitted to a clinical microbiological laboratory in an urban academic medical center.

***Methods.*** Study urines (N = 966) were obtained as de-identified discarded specimens from the University of Washington Medical Center microbiology laboratory. SLRC\'s immunoassay test was performed in accordance with instructions, providing a +/- result in about 15 minutes. Standard urine cultures were performed in parallel and all organisms were identified to the species level.

***Results.*** 79% of urine specimens were from an outpatient setting and 21% were from inpatients. With urine culture used as the gold standard, the SLRC test kit identified as positive 244/270 (sensitivity 90%) of samples with *E*. *coli* or species of the genera *Klebsiella*, *Proteus*, *Citrobacter*, *Pseudomonas*, *Serratia*, *Acinetobacter* or *Enterobacter* at a level of ≥10^3^ CFU/ml. The specificity of the test on samples with \<10^3^ CFU/ml of Gram negative uropathogens was 94% (523/555).

***Conclusion.*** A new rapid immunoassay test kit for direct detection of Gram negative bacteriuria in patient urine samples performed at high sensitivity (90%) and specificity (94%) as compared with standard culture of urine samples from both outpatient and inpatient settings. Using this assay in point-of-care diagnosis of UTI has the potential to reduce cost of treatment and overuse of antimicrobials for this common infection.
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